-
A drug which has been used for decades to treat high blood pressure may turn out to be a key treatment for multiple sclerosis, say British researchers.
-
The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS.
-
TRIMESTA (oral estriol), its proprietary therapy for multiple sclerosis (MS), in a multi-center Phase II/III clinical trial for the treatment of women with relapsing-remitting MS.
-
Here is a table of clinical trials of Rebif.
-
The MS-F204 study, which is conducted under a Special Protocol Assessment (SPA) issued by the Food and Drug Administration (FDA), will evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS.
-
the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis
-
The data suggest that FTY720 may have the potential to reduce neurodegeneration and enhance repair of the central nervous system (CNS) by modulating S1P receptors expressed on brain cells.
-
Positive clinical findings from the 12-month core period of a Phase II clinical trial of MN-166 that measures both surrogate (radiological) and clinical outcomes over two years of treatment in 297 patients with relapsing multiple sclerosis (MS).
-
In the latest trial, daclizumab was given in combination with a standard therapy, interferon-beta, and was effective up to 24 weeks, the companies said in a statement.
-
Artielle ImmunoTherapeutics, Inc. today announced that the company has initiated a Phase I clinical trial to evaluate its novel drug candidate, RTL1000, for the treatment of multiple sclerosis (MS). RTL1000 is a novel protein drug
-
This month a UCLA researcher begins a widespread clinical trial of the female sex hormone estriol, produced during pregnancy, which she’s shown sharply reduces the symptoms of multiple sclerosis.
-
Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
-
The TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study is testing Tovaxin, an autologous T-Cell vaccination in patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
-
Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
-
"The clearance to proceed with a phase III trial in the US is asignificant step towards bringing MBP8298 to the worldwide market," saidKevin Giese, President and CEO of BioMS Medical.
